- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.12.24 | AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2 | ||
| 11.12.24 | Jury convicts ex-CytoDyn CEO on 9 counts tied to biotech fraud | ||
| 11.12.24 | Candel burns bright as phase 3 prostate cancer win sends stock up 200% | ||
| 11.12.24 | Angitia raises $120M series C to fund trio of musculoskeletal trials | ||
| 11.12.24 | Capstan Medical collects $110M for robotic heart valve replacements | ||
| 11.12.24 | Q32's stock plunges in wake of phase 2 eczema fail for anti-IL-7R antibody | ||
| 11.12.24 | 2 Boston-area biotechs shed staff, fuse to form genetic medicines company nChroma Bio | ||
| 11.12.24 | BenevolentAI pivots back to 'TechBio' roots, causing more layoffs | ||
| 11.12.24 | Cellectar lays off 60% of staff, ditches lead radiotherapy over FDA demand for another trial | ||
| 11.12.24 | Spruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubt | ||
| 10.12.24 | In midstage colorectal cancer trial, Cardiff's KRAS candidate linked to 64% response rate at higher dose | ||
| 10.12.24 | Artivion nets FDA humanitarian green light for prosthetic aortic tear implant | ||
| 10.12.24 | Roche said it didn't want to buy Poseida last year: A look at how the $1.5B buyout came to be | ||
| 10.12.24 | FDA clears AngioDynamics' NanoKnife pulsed field ablation system for prostate cancer | ||
| 10.12.24 | Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup | ||
| 10.12.24 | BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer | ||
| 10.12.24 | NewAmsterdam's stock rises on early sign cholesterol drug improves cardiovascular outcomes | ||
| 10.12.24 | CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial | ||
| 10.12.24 | GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets | ||
| 10.12.24 | Health tech firm Carta Healthcare buys AI company that matches patients to cancer trials | ||
| 09.12.24 | Belharra's tide falls as the chemoproteomics biotech lays off 21 workers | ||
| 09.12.24 | Relmada turns to strategic options after scrapping 2 phase 3 trials | ||
| 09.12.24 | Gene therapy reduces seizures, improves cognitive and motor function in mice with severe epilepsy | ||
| 09.12.24 | Carisma axes sole clinical cell therapy candidate, lays off 23 workers | ||
| 09.12.24 | Cala Health raises $50M to spark growth of its wearable hand tremor therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
